Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tessera: engineering mobile genetic elements for gene insertion

Flagship newco Tessera uses mobile genetic elements to make gene insertions

Tessera Therapeutics, the latest company to emerge from Flagship Pioneering, is developing a suite of gene editing tools based on mobile genetic elements that have the potential to create a broader range of genomic alterations than CRISPR.

The company came out of stealth on Tuesday with over $50 million in funding from Flagship, two years of research supporting its Gene Writing

Read the full 612 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers